Eli Lilly and Company has received FDA approval for its IL-13 inhibitor, Ebglyss (lebrikizumab), to treat moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 and above. Ebglyss joins a growing list of new drug approvals for Lilly, including Mounjaro, Zepbound, Omvoh, and Jaypirca, all contributing to the company’s strong financial performance. The company’s stock has outperformed the industry, sector, and S&P 500, with its new drugs driving significant revenue growth.
The FDA has approved Eli Lilly’s Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for adults and children with moderate-to-severe atopic dermatitis (eczema) that doesn’t respond well to topical treatments. Ebglyss targets eczema inflammation throughout the body, leading to significant improvement in skin dryness, itching, and irritation. The drug’s effectiveness was proven in clinical trials, with a substantial percentage of patients achieving clear or almost-clear skin and itch relief.
